Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
22 Fevereiro 2024 - 10:00AM
Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a
clinical-stage biopharmaceutical company developing novel
therapeutics for the treatment of rare diseases, today announced
that Anish Bhatnagar, M.D., Chief Executive Officer, will present
at the TD Cowen 44th Annual Healthcare Conference on Monday, March
4, 2024, at 1:30 PM Eastern Time.
A live audio webcast and replay of the presentation will be
available in the Investors section on the Company’s website at
www.soleno.life.
About Soleno Therapeutics, Inc.Soleno is
focused on the development and commercialization of novel
therapeutics for the treatment of rare diseases. The company’s lead
candidate, DCCR extended-release tablets, a once-daily oral tablet
for the treatment of PWS, recently completed its Phase 3
development program to support a planned NDA submission. For more
information, please visit www.soleno.life.
Corporate Contact:Brian RitchieLifeSci
Advisors, LLC212-915-2578
Soleno Therapeutics (NASDAQ:SLNO)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Soleno Therapeutics (NASDAQ:SLNO)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024